- England’s National Institute for Health and Care Excellence (NICE). recommended BeiGene Ltd BGNE Brukinsa (zanubrutinib) for Waldenstrom’s macroglobulinemia (WM) in adults who have received at least one treatment, only if bendamustine plus rituximab is also appropriate.
- This NICE decision marks Brukinsa as the first and only treatment for WM recommended for routine use in England and Wales.
- Also read: BeiGene’s Brukinsa outperforms JNJ’s Imbruvica in overall response rate in a leukemia study.
- WM is a rare form of B-cell lymphoma that occurs in less than two percent of patients with non-Hodgkin lymphoma. Around 4,000 people live with MW in the UK
- The NICE recommendation states that Brukinsa is considered cost-effective above a threshold of £20,000-30,000 per quality-adjusted life-year.
- Also the Committee for Medicinal Products for Human Use of the European Medicines Agency supported Brukinsa’s approval for marginal zone lymphoma patients who have received at least one prior anti-CD20-based therapy.
- Price promotion: BGNE shares closed 1.45% lower at $154.82 on Monday.
